For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit

Imago: A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia

Clinical Trial Details

The purpose of this study is to evaluate the effectiveness of IMG-7289 as a treatment option for essential thrombocythemia (ET) that has not responded adequately to at least one current standard therapy. IMG-7289 is an orally administered LSD1 inhibitor aimed at suppressing disease cells.

Study participants will be monitored for changes in blood counts and disease related symptoms, as well as how they tolerate IMG-7289 and how doses impact each patient’s disease.

This is an open-label study, which means both you and your study doctor know what dose of IMG-7289 you are receiving, and the initial treatment period is 24 weeks long consisting of 10 study visits.

IMG-7289 is considered investigational, which means that it has not been approved by the US Food and Drug Administration (FDA).

Key Eligibility: 
  • A documented diagnosis of essential thrombocythemia per the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms
  • Past failure of at least one standard therapy for essential thrombocythemia
  • An individual requiring  treatment in order to lower platelet counts based on either patient age (over 60) or a history of thrombosis.

Detailed eligibility criteria will be reviewed with the study team.


Study contact by location

Upper East Side - Manhattan


Tania J. Curcio, NP, FNP-BC
(212) 746-2571

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:




Open to Enrollment

Age Group